A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
Latest Information Update: 07 May 2025
At a glance
- Drugs Lonapegsomatropin (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Acronyms SkyPASS
- Sponsors Ascendis Pharma
Most Recent Events
- 18 Apr 2023 Status changed from not yet recruiting to recruiting.
- 22 Mar 2023 New trial record